Rifampicin: a new orally active rifamycin - PubMed (original) (raw)

• PMID: 5958716
• DOI: 10.1159/000220462

Rifampicin: a new orally active rifamycin

N Maggi et al. Chemotherapy. 1966.

No abstract available

PubMed Disclaimer

Similar articles

• Multiple emulsions containing rifampicin.
  Khopade AJ, Jain NK. Khopade AJ, et al. Pharmazie. 1999 Dec;54(12):915-9. Pharmazie. 1999. PMID: 10631755 Clinical Trial.
• [Early results of rifampicin treatment combined with other antitubercular agents in patients with recent and chronic pulmonary tuberculosis].
  Zduńczyk-Pawełek H, Kochnowski G, Polońska A. Zduńczyk-Pawełek H, et al. Pneumonol Pol. 1979 Feb;47(2):97-105. Pneumonol Pol. 1979. PMID: 432119 Polish. No abstract available.
• Preparation, properties and metabolism of 5,6-monoepoxyretinoic acid.
  John KV, Lakshmanan MR, Cama HR. John KV, et al. Biochem J. 1967 May;103(2):539-43. doi: 10.1042/bj1030539. Biochem J. 1967. PMID: 6032985 Free PMC article.
• Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
  van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. van Ingen J, et al. Clin Infect Dis. 2011 May;52(9):e194-9. doi: 10.1093/cid/cir184. Clin Infect Dis. 2011. PMID: 21467012 Review.
• The near future: improving the activity of rifamycins and pyrazinamide.
  Mitchison DA, Fourie PB. Mitchison DA, et al. Tuberculosis (Edinb). 2010 May;90(3):177-81. doi: 10.1016/j.tube.2010.03.005. Epub 2010 Apr 9. Tuberculosis (Edinb). 2010. PMID: 20382083 Review.

Cited by

• Rifampicin Resistant Tuberculosis Among Presumptive Pulmonary Tuberculosis in Province Referral Hospital, Indonesia: Dynamic Cases of a 7-Year Report.
  Maulina N, Hayati Z, Hasballah K, Zulkarnain Z, Waraztuty I, Defadheandra A. Maulina N, et al. J Res Health Sci. 2024 Mar 18;24(1):e00601. doi: 10.34172/jrhs.2024.136. Epub 2024 Mar 15. J Res Health Sci. 2024. PMID: 39072537 Free PMC article.
• Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma.
  Zhang H, Luo P, Huang X. Zhang H, et al. Front Pharmacol. 2023 Aug 21;14:1269224. doi: 10.3389/fphar.2023.1269224. eCollection 2023. Front Pharmacol. 2023. PMID: 37670948 Free PMC article. Review.
• C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus.
  Paulowski L, Beckham KSH, Johansen MD, Berneking L, Van N, Degefu Y, Staack S, Sotomayor FV, Asar L, Rohde H, Aldridge BB, Aepfelbacher M, Parret A, Wilmanns M, Kremer L, Combrink K, Maurer FP. Paulowski L, et al. PNAS Nexus. 2022 Aug 9;1(4):pgac130. doi: 10.1093/pnasnexus/pgac130. eCollection 2022 Sep. PNAS Nexus. 2022. PMID: 36714853 Free PMC article.
• In vitro Dissolution Testing of Rifampicin Powder Formulations For Prediction of Plasma Concentration-Time Profiles After Inhaled Delivery.
  Khadka P, Tucker IG, Das SC. Khadka P, et al. Pharm Res. 2023 May;40(5):1153-1163. doi: 10.1007/s11095-022-03439-z. Epub 2022 Nov 29. Pharm Res. 2023. PMID: 36447019
• Activation of Dynamin-Related Protein 1 and Induction of Mitochondrial Apoptosis by Exosome-Rifampicin Nanoparticles Exerts Anti-Osteosarcoma Effect.
  Chen W, Lin W, Yu N, Zhang L, Wu Z, Chen Y, Li Z, Gong F, Li N, Chen X, He X, Wu Y, Zeng X, Yueh Y, Xu R, Ji G. Chen W, et al. Int J Nanomedicine. 2022 Nov 18;17:5431-5446. doi: 10.2147/IJN.S379917. eCollection 2022. Int J Nanomedicine. 2022. PMID: 36426375 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • S. Karger AG, Basel, Switzerland

• Other Literature Sources

  • The Lens - Patent Citations